Dual-responsive magnetic and pH-sensitive hydrogel beads for controlled cisplatin delivery in glioblastoma cells
- PMID: 40490655
- DOI: 10.1007/s12032-025-02815-0
Dual-responsive magnetic and pH-sensitive hydrogel beads for controlled cisplatin delivery in glioblastoma cells
Abstract
Glioblastoma (GB) is a highly aggressive brain tumor with poor prognosis due to its invasiveness and resistance to conventional therapies, necessitating advanced drug delivery systems to enhance treatment efficacy and reduce toxicity. This study aims to develop and evaluate dual-responsive magnetic and pH-sensitive beads for controlled cisplatin delivery to glioblastoma cell lines, addressing challenges in targeted therapy. Cobalt ferrite (CoFe2O4) nanoparticles were synthesized via a green co-precipitation method using clove extract as an alkalizing and stabilizing agent. These nanoparticles were incorporated into sodium alginate beads with cisplatin, cross-linked by Ca2+ ions. Beads were characterized using FTIR, XRD, SEM, and VSM. Swelling behavior, encapsulation efficiency, and in vitro drug release were assessed at pH 1.2 and 7.4, with and without a magnetic field. Cytotoxicity was evaluated via MTT assay on T98, A172, and L929 cell lines. The beads exhibited pH-dependent swelling, with maximum absorption at pH 7.4. Drug release was significantly enhanced under a 100 Hz magnetic field, achieving 70.2% cisplatin release in 80 min for CisB-4 beads. MTT assays demonstrated significant cytotoxicity against T98 and A172 cells (p < 0.05 to p < 0.0001), with minimal toxicity to normal L929 cells. These dual-responsive beads offer a promising platform for targeted cisplatin delivery in glioblastoma, with pH and magnetic field-mediated control, potentially improving therapeutic outcomes while minimizing systemic toxicity.
Keywords: Cisplatin; Controlled drug delivery; Glioblastoma; Magnetic beads; pH-sensitive.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethical approval: The study gained the approval of the ethical committee of the Kerman University of Medical Sciences. Consent to participate: All participants were provided written informed consent during the study. All methods were performed in accordance with the relevant guidelines and regulations. Consent for publication: Not applicable.
Similar articles
-
Development of a Multi-Stimuli-Responsive Magnetic Nanogel-Hydrogel Nanocomposite for Prolonged and Controlled Doxorubicin Release.Bioconjug Chem. 2025 Aug 20;36(8):1604-1627. doi: 10.1021/acs.bioconjchem.5c00083. Epub 2025 May 14. Bioconjug Chem. 2025. PMID: 40367204
-
Active targeted delivery of theranostic thermo/pH dual-responsive magnetic Janus nanoparticles functionalized with folic acid/fluorescein ligands for enhanced DOX combination therapy of rat glioblastoma.J Mater Chem B. 2024 Jun 19;12(24):5957-5973. doi: 10.1039/d3tb02429f. J Mater Chem B. 2024. PMID: 38808630
-
Metformin loaded Mn3O4@SiO2 core-shell nanoparticles for glioblastoma multiforme targeted therapy.Colloids Surf B Biointerfaces. 2025 Oct;254:114789. doi: 10.1016/j.colsurfb.2025.114789. Epub 2025 May 14. Colloids Surf B Biointerfaces. 2025. PMID: 40393097
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
References
-
- Yeini E, Ofek P, Albeck N, Rodriguez Ajamil D, Neufeld L, Eldar-Boock A, et al. Targeting glioblastoma: advances in drug delivery and novel therapeutic approaches. Adv Ther. 2021;4(1):2000124.
-
- McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021. https://doi.org/10.1136/bmj.n1560 . - DOI - PubMed
-
- Elleaume H, Barth RF, Rousseau J, Bobyk L, Balosso J, Yang W, et al. Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma. J Neurooncol. 2020;149(2):193–208. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous